Destiny And SporeGen Back Nasal Spray Over Vaccine To Tackle COVID-19
Easy To Use And Produce
The SPOR-COV prophylactic approach targets the innate immune system and has the potential to develop COVID-19 protection within a few days of treatment, the partners tell Scrip.
You may also be interested in...
Destiny Pharma's XF-73 achieved an "exceptionally high" 99.5% reduction in Staphylococcus aureus bacterial nasal carriage in a mid-stage trial, a result that should attract a number of potential partners for the UK firm.
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.
BenevolentAI has added Merck KGaA to its list of partners but the UK firm is looking for a new CEO after Joanna Shields decided to leave as a major restructuring continues.